Clinical Trial Detail

NCT ID NCT02041260
Title A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Exelixis
Indications

thyroid gland cancer

Therapies

Cabozantinib

Age Groups: adult

No variant requirements are available.